MSAC brands J&J 'unethical'

MSAC has branded a pricing proposal by Johnson & Johnson Innovative Medicine as 'unethical' - exposing the depth of bitterness in negotiations which have ended with the company's CAR T therapy for multiple myeloma, Carvykti, finally winning a recommendation.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here